Merck Performs Its Own Clinical Trial on Vioxx - APPROVe - See What They Conclude
APPROVe [Adenomatous Polyp Prevention on Vioxx] was a study conducted by Merck & Co. Inc, to determine the effects of rofecoxib (Vioxx®) on the recurrence of adenomatous polyps of the large intestines in users who have had a prior history of colorectal adenomas. This was a multi-center, placebo-controlled, randomized, double-blind study to determine the effects Vioxx has on these conditions in a span of 3 years. The study included 2600 (62% male) patients ranging from the age of 40 to 96 years of age where they were allowed to use Aspirin.
On 30 September 2004 APPROVe was terminated when it was discovered that there was a confirmed risk for cardiovascular events (i.e. heart attack and stroke) only after 18 months of chronic use.
If you or a loved one has suffered due to a side effect of Vioxx, you can fill out this simple form for a free case review within 24 hours.
Weitz & Luxenberg is no longer accepting Vioxx cases.
see also:
VICTOR
VICTOR - Merck's Incomplete Study on Vioxx What went wrong? Learn about VICTOR the Vioxx study that was cut short
APPROVe
What happens when Merck tests its own drug Vioxx? APPROVe happensRead about Vioxx's Clinical Trial APPROVe & see what Merck discovered
Vioxx Clinical Trials
Want some history? See the Vioxx Clinical Trials & FDA Studies chartWhat you need to know about Vioxx - Clinical Trials & FDA Studies
